In the News

A retrospective study from MSK has found that colorectal cancer patients with liver metastases live an average of two years longer when they receive an additional treatment called hepatic arterial infusion (HAI).

MSK surgeon James Eastham explains the pros and cons of PSA testing and weighs in on a new US Preventive Services Task Force guideline.

Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at [email protected].

Learn more about entrectinib, a targeted therapy being evaluated in patients with solid tumors.

A team at MSK uncovered how TRX518, a new immunotherapy drug in early development, works in the body.

Leukemia patients may do better on CAR T cell therapy when they are treated early, before their disease relapses.

For some patients with metastatic melanoma, a combination of two immunotherapies works better than either drug alone.

Neratinib, which targets mutations that drive cancer growth, is showing promise for treating several types of cancer.

Researchers find an epigenetic role in how breast cancer tumors develop resistance to treatment.